Summary
Thermo Fisher Scientific Inc. (TMO) has officially terminated its Business Combination Agreement with QIAGEN N.V. as of August 13, 2020. This decision follows the lapse of Thermo Fisher's public tender offer to acquire QIAGEN, which was due to an unfulfilled offer condition. The termination was executed in accordance with the terms of the agreement. While the acquisition has been called off, QIAGEN will provide Thermo Fisher with an expense reimbursement payment of $95,000,000 in cash. This filing serves to formally announce the termination and associated financial reimbursement, marking the end of this significant potential transaction and allowing Thermo Fisher to redirect resources and strategic focus.
Key Highlights
- 1Thermo Fisher Scientific has terminated its Business Combination Agreement with QIAGEN N.V.
- 2The termination was a result of an unfulfilled offer condition for the tender offer to acquire QIAGEN.
- 3QIAGEN will pay Thermo Fisher $95,000,000 in cash as an expense reimbursement.
- 4The company issued a press release on August 13, 2020, to announce the lapse of the offer and the termination of the agreement.
- 5This filing (8-K) formally documents the termination of a material definitive agreement.